7 completed. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Blepharospasm: new trials by email Literature Review of Blepharospasm trials Research Report on Blepharospasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Dipraglurant, Placebo - Blepharospasm, Dystonia | Phase 2 | Completed | Addex Pharma S.A. | 15 | 2021-10-06 | 2025-10-03 |
| Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Cannabidiol Oral Solution [Epidiolex] - Blepharospasm, Blepharospasm, Benign Essential | Phase 2 / Phase 3 | Completed | Silkiss Eye Surgery | 12 | 2020-05-20 | 2021-11-02 |
| Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Clostridium Botulinum Toxin Type A - Blepharospasm | Phase 2 / Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 234 | 2016-10-01 | 2019-06-26 |
| A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm Acetyl-Hexapeptide Topical Treatment, placebo - Focal Dystonia | Phase 1 / Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2009-07-01 | 2012-09-06 |
| Brain Stimulation to Treat Blepharospasm or Meige Syndrome repetitive transcranial magnetic stimulation (rTMS) - Blepharospasm, Focal Dystonia | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 22 | 2006-06-22 | 2017-07-02 |
| Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Botulinum toxin type A - Blepharospasm | Phase 2 | Completed | Ipsen | 120 | 2003-01-01 | 2019-07-29 |
| Mexiletine for the Treatment of Focal Dystonia Mexiletine - Blepharospasm, Dystonia | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 1998-07-01 | 2008-03-04 |
Dystonia (4) · Dystonic Disorders (3) · Benign essential blepharospasm (1) · Spasm (1)
Eye Diseases (7) · Eyelid Diseases (7) · Dyskinesias (4) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Central Nervous System Diseases (3) · Movement Disorders (3) · Neuromuscular Manifestations (1)
Botulinum Toxins, Type A (2) · 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (1) · Cannabidiol (1) · Mexiletine (1) · Transcranial Magnetic Stimulation (1) · abobotulinumtoxinA (1)
National Institute of Neurological Disorders and Stroke (NINDS) (3) · Addex Pharma S.A. (1) · Daewoong Pharmaceutical Co. LTD. (1) · Ipsen (1) · Silkiss Eye Surgery (1)
United States (6) · South Korea (1)